Share subscriptions based on Nanoform Finland Plc’s stock options 1/2019 and 2/2019
Company release Nanoform Finland Plc December 5, 2023 18.00 Finnish…
(b)(2) or not to be, that is the question
USFDA 505(b)(2) pathway submissions (“(b)(2)s”) can be advantageous because they…
Nanoform Finland Plc – Manager’s transactions – Miguel Calado
Company release Nanoform Finland Plc November 29, 2023 09.00 Finnish…
Nanoform Finland Plc – Manager’s transactions – Albert Hæggström
Company release Nanoform Finland Plc November 29, 2023 09.00 Finnish…
Nanoform Finland Plc – Manager’s transactions – Mads Laustsen
Company release Nanoform Finland Plc November 29, 2023 09.00 Finnish…
Nanoform Finland Plc – Manager’s transactions – Jeanne Thoma
Company release Nanoform Finland Plc November 29, 2023 09.00 Finnish…
Nanoform Q3 2023: Nanoformed blockbuster drug enters clinic and another nanoformed drug received FDA orphan designation
Company Announcement Nanoform Finland Plc November 22, 2023 08:10 a.m.…
Interim Report January-September 2023
Nanoform published its Q3 2023 interim report on November 22, 2023, at 8.10 a.m. Finnish time / 7.10 a.m. Swedish time.